CDTX
Cidara Therapeutics
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Cidara Therapeutics reached target enrollment for Phase 3 ANCHOR trial evaluating CD388 to prevent seasonal influenza in high-risk populationsNov 24, 2025
- Cidara Therapeutics announces late-breaking Phase 2b data presentation on CD388 at ID Week 2025Oct 21, 2025
- Cidara Therapeutics to present late-breaking Phase 2 clinical data on CD388 at ID Week 2025Oct 13, 2025
- Cidara Therapeutics receives U.S. FDA breakthrough therapy designation for CD388 in seasonal influenza preventionOct 9, 2025
- Cidara Therapeutics announces first participants dosed in Phase 3 ANCHOR trial evaluating CD388 for prevention of seasonal influenza in high-risk populationsSep 26, 2025